Fulcrum Therapeutics, Inc. FULC
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | 31.61% | -2.34% | -- |
| Gross Profit | -- | -- | -31.61% | 2.34% | -- |
| SG&A Expenses | 9.29% | 15.76% | -5.69% | -10.23% | -33.37% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.46% | 8.74% | 16.80% | -5.22% | -27.97% |
| Operating Income | -0.46% | -8.74% | -16.80% | 5.22% | -137.75% |
| Income Before Tax | -51.36% | -7.00% | -22.73% | 9.68% | -131.22% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -51.36% | -7.00% | -22.73% | 9.68% | -131.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -51.36% | -7.00% | -22.73% | 9.68% | -131.22% |
| EBIT | -0.46% | -8.74% | -16.80% | 5.22% | -137.75% |
| EBITDA | -1.12% | -8.97% | -17.24% | 5.21% | -136.83% |
| EPS Basic | -24.16% | 12.28% | -0.65% | 9.95% | -131.04% |
| Normalized Basic EPS | 20.43% | 12.29% | -0.68% | 0.51% | -131.04% |
| EPS Diluted | -24.16% | 12.28% | -0.35% | 10.57% | -131.78% |
| Normalized Diluted EPS | 20.43% | 12.29% | -0.68% | 0.51% | -131.73% |
| Average Basic Shares Outstanding | 21.94% | 21.98% | 21.92% | 0.30% | 0.54% |
| Average Diluted Shares Outstanding | 21.94% | 21.98% | 21.92% | 0.30% | -1.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |